Word: genentech
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
DRUG WARNING Since its debut in 1998, Herceptin has stemmed the growth of breast cancer in tens of thousands of women. But now its maker, Genentech, is alerting doctors to possible adverse reactions and even death in a small percentage of patients who have a history of lung problems and did not respond to chemotherapy. A new label in the works will help doctors select the patients best suited for the gene-spliced drug. --By Janice M. Horowitz...
...drugs approved today are coming out of the biotech sector," says Jim McCamant, editor of the Medical Technology Stock Letter in Berkeley, Calif. Some 350 biotech products are in trials, and more than 100 are on the market. Among recent blockbusters: Herceptin, a breast-cancer treatment from Genentech, and Enbrel, an arthritis medication from Immunex. Yet a few standouts hardly guarantee the success of an entire industry. That's where gene mapping becomes critical...
After graduating from Northwestern, Peralta received a doctorate from Indiana University in 1986. His work at a San Francisco-based biotechnology firm, Genentech, attracted several tenure offers--and Harvard...
...Genentech backed the idea. At the time, European researchers had reported that the biotech company's clot-busting drug, TPA, worked no better, yet cost far more, than the standard clot buster. If TPA was to survive, it had to quantify its benefits to insurers. With a fortune on the line, Genentech turned to Califf. Within two years, Califf and the Cleveland Clinic organized a network that enrolled 41,000 patients. Conclusion: compared with the standard drug, TPA saved more than 2,000 lives a year...
...drug to go around, and that's not always the case. Beth Nocera of Medford, Mass., a 41-year-old mother of two, has terminal metastatic breast cancer. Nocera wants to try Herceptin, an anticancer drug now in clinical trials. But Herceptin is expensive, and the manufacturer, Genentech, isn't making much beyond what it needs for testing. It currently gives the extra Herceptin to a limited number of women, chosen at random by a computer, and Nocera's number hasn't come up yet. "My fear," she says, "is that it's all about money and that these companies...